Venture Capital

Montreal’s Inversago raises $95-million led by NEA to revive failed class of weight-loss drugs


A Montreal biotechnology company trying to resuscitate a class of weight-loss drugs with a troubled past has raised $95-million from investors to take its lead molecule into human trials to see if it works as intended. Inversago Pharma Inc. drew the funding from lead investor New Enterprise …

Read more

Show More

Related Articles

Back to top button